Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Non-cash Items (2023 - 2025)

CG Oncology's Non-cash Items history spans 3 years, with the latest figure at $198.5 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 83.57% year-over-year to $198.5 million; the TTM value through Dec 2025 reached $198.5 million, up 83.57%, while the annual FY2025 figure was $198.5 million, 83.57% up from the prior year.
  • Non-cash Items reached $198.5 million in Q4 2025 per CGON's latest filing, up from $190.7 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $231.2 million in Q1 2024 to a low of $40.3 million in Q4 2023.
  • Average Non-cash Items over 3 years is $141.5 million, with a median of $153.0 million recorded in 2024.
  • Peak YoY movement for Non-cash Items: surged 168.44% in 2024, then tumbled 62.23% in 2025.
  • A 3-year view of Non-cash Items shows it stood at $40.3 million in 2023, then soared by 168.44% to $108.2 million in 2024, then soared by 83.57% to $198.5 million in 2025.
  • Per Business Quant, the three most recent readings for CGON's Non-cash Items are $198.5 million (Q4 2025), $190.7 million (Q3 2025), and $106.8 million (Q2 2025).